Safety of short versus extended antibiotic therapy for neutropenic fever after hematopoietic cell transplantation
Antimicrobial Stewardship & Healthcare Epidemiology · 2026 · 6 (1)
DOI: 10.1017/ash.2026.10327 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Stewardship & Healthcare Epidemiology, online erschienen am 23.03.2026. Verfasst von Lucy Cai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Scripps Green Hospital, Torrey Pines, CA, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To determine safety and effectiveness of short (≤7 d) versus extended (>7 d) antibiotic courses for neutropenic fever in HCT recipients.
Design
Retrospective cohort study.
Setting
Private tertiary referral center.
Participants
Consecutive sample; all patients >18 years old admitted between January 2019 and May 2024 with neutropenic fever during their index hospitalization for HCT.
Methods
Data were collected via chart review. Primary outcomes were clinical failure (30-day mortality or ICU admission) and adverse events ( Clostridioides difficile infection or acute kidney injury [AKI]). Secondary outcomes included recurrent fever and length of stay (LOS). Multivariable logistic regression adjusted for age, sex, transplant type, infection type, and malignancy.
Results
Among 103 patients (55 short, 48 extended), mean antibiotic duration was 3.6 days (short) and 11.9 days (extended). There were more leukemia and allogeneic HCT recipients in the extended group. In multivariable analyses, antibiotic duration was not predictive of clinical failure (odds ratio [OR] 3.40; 95% confidence interval [CI], 0.50–27.55; P = .222) or composite adverse events (OR, 3.72; 95% CI, 0.94–16.22; P = .067), although the odds of AKI were greater in the extended group (OR, 4.72; 95% CI, 1.08–23.68; P = .046). Recurrent fever was uncommon. LOS was greater in the extended group (43.4 d vs 21.4 d; P = .032).
Conclusions
We found that shorter antibiotic courses were not associated with worse clinical outcomes or adverse events in HCT patients with neutropenic fever in the early posttransplant period. These findings support emerging evidence favoring shorter therapy.
Autor:innen und Institutionen
- Scripps Green Hospital, Torrey Pines, CA, USA.
- Scripps Health, La Jolla, CA, USA.
ORCID-Profile: Lucy Cai, Leah Puglisi, Miguel Goicoechea
Zitieren
APA
Cai, L., Puglisi, L., Molina, K. C., & Goicoechea, M. (2026). Safety of short versus extended antibiotic therapy for neutropenic fever after hematopoietic cell transplantation. Antimicrobial Stewardship & Healthcare Epidemiology, 6(1). https://doi.org/10.1017/ash.2026.10327
Vancouver
Cai L, Puglisi L, Molina KC, Goicoechea M. Safety of short versus extended antibiotic therapy for neutropenic fever after hematopoietic cell transplantation. Antimicrobial Stewardship & Healthcare Epidemiology. 2026;6(1). doi:10.1017/ash.2026.10327
BibTeX
@article{Cai2026,
author = {Cai, Lucy and Puglisi, Leah and Molina, Kyle C and Goicoechea, Miguel},
title = {Safety of short versus extended antibiotic therapy for neutropenic fever after hematopoietic cell transplantation},
journal = {Antimicrobial Stewardship & Healthcare Epidemiology},
year = {2026},
volume = {6},
number = {1},
doi = {10.1017/ash.2026.10327}
}
EUVIMED